An interventional study of Intravascular Lithotripsy and Cutting Balloon in Treatment in Calcified Coronary Disease, sponsored by Baim Institute for Clinical Research. Completed at 22 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Baim Institute for Clinical Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.
Among the 274 studies in Coronary Disease with a site in United States, this one is the 66th largest by enrollment of the 184 interventional ones that give a count, is one of 3 that started in 2023, is one of 78 with no phase, and was the 263rd registered.
1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
West Virginia School of Osteopathic Medicine · Sites in United States
Ages 18–64
University of California, Los Angeles · Sites in United States
Ages 60–80
Weill Medical College of Cornell University · Sites in United States, Austria, Canada and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
274 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 43 · Phase 3 36 · Phase 4 18
First in 1973; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 160 across 779 interventional studies indexed under Coronary Disease.
Median enrollment 200 across the 184 interventional studies, 324 across the 87 observational. Of the 235 that completed or were terminated, 88 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 274 have an industry lead sponsor. The 10 most frequent:
Baim Institute for Clinical Research is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Baim Institute for Clinical Research has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
| NCT06170541Johns Hopkins UniversityCORE-COMPARE Pilot Study | 2026-12 |
| NCT05918380University Hospitals Cleveland Medical CenterProject 3: ACHIEVE- CHD | 2027-01-01 |
| NCT00406185Intermountain Health Care, Inc.Database Registry of the Intermountain Heart Collaborative Study | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 274 studies in Coronary Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
The trial will be composed of two cohorts:
Randomization to either cutting balloon angioplasty or intravascular lithotripsy will occur as follows in the 2 cohorts:
The trial is designed to demonstrate non-inferiority between cutting balloon angioplasty and intravascular lithotripsy in each cohort with regards to the primary endpoint of post-procedural stent area as measured by intravascular imaging at the site of maximal calcification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Subject is > 21 years old 2. Subject with an indication for PCI for the treatment of a) stable coronary artery disease; b) unstable angina; or c) NSTEMI with evidence of down-trending biomarkers 3. Subject is willing and able to provide informed written consent Angiographic Inclusion Criteria
The target vessel is a native coronary artery with either:
The target lesion has evidence of significant calcium at the lesion site defined either as,
Exclusion Criteria:
<!-- -->
Patient has suffered a recent cerebrovascular event (stroke/) within last 30 days
Angiographic Exclusion Criteria
<!-- -->
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Intravascular Lithotripsy
Device: Cutting Balloon
Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Primary Endpoint
Post-procedural stent area at the point of maximum calcification as measured by intravascular imaging
Time frame: 30 days
Procedural Cost
Time frame: Index procedure
Procedural success
Procedural success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g. severe dissection, perforation, abrupt closure or no-reflow) with final TIMI 3 flow in the target vessel and the absence of intra-procedural death
Time frame: Index procedure
Angiographic success
Angiographic success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g. severe dissection, perforation, abrupt closure or no-reflow)
Time frame: Index procedure
Strategy success
Strategy success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g., severe dissection, perforation, abrupt closure or no-reflow and not having to use an alternative calcium modification device (e.g. atherectomy device or specialty balloon other than routine non-compliant balloon)
Time frame: Index procedure
Peri-procedural Myocardial Infarction
Peri-procedural Myocardial Infarction as defined by Academic Research Consortium-2
Time frame: within 48 hours of index procedure
In-hospital MACCE
In-hospital MACCE defined as composite of all-cause death, unplanned urgent target vessel revascularization, unplanned cardiothoracic surgery, spontaneous myocardial infarction or stroke/TIA at hospital discharge.
Time frame: hospitalization
30 Day MACCE
30 Day MACCE defined as composite of all-cause death, unplanned target vessel revascularization, unplanned cardiothoracic surgery, spontaneous myocardial infarction or stroke/TIA at 30 days
Time frame: 30 days
Plan to share: No
Ran from Dec 2023 to primary completion in Aug 2025, 19 months.
Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 19 months is below that.
Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baim Institute for Clinical Research